MedTrace Logo

Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes

NCT00044408 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2016-07-26

No results posted yet for this study

Summary

The purpose of this protocol is to determine if an investigational drug known as LY333531 is effective in treating nerve malfunction in diabetes.

Conditions

  • Diabetic Neuropathies
  • Diabetes Mellitus, Insulin-Dependent
  • Diabetes Mellitus, Non-Insulin-Dependent

Interventions

DRUG

Ruboxistaurin mesylate

Sponsors & Collaborators

  • Chromaderm, Inc.

    lead INDUSTRY

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-07-31
Completion
2005-10-31

Countries

  • United States
  • Canada
  • Croatia
  • Finland
  • India
  • Lithuania
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00044408 on ClinicalTrials.gov